STOCK TITAN

23andMe Holding Co - ME STOCK NEWS

Welcome to our dedicated news page for 23andMe Holding Co (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 23andMe Holding Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 23andMe Holding Co's position in the market.

Rhea-AI Summary
23andMe Holding Co. reported a decrease in total revenue for the third quarter of fiscal 2024 compared to the same period in the prior year. This was primarily driven by lower research services revenue due to the conclusion of the GSK collaboration exclusivity term and lower consumer services revenue. The company announced a new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on a novel, dual-mechanism immuno-oncology asset. Additionally, 23andMe expanded its BRCA1/BRCA2 Genetic Health risk report and presented updated data for its Phase 1/2a study at the Society for Immunotherapy of Cancer conference. The company's net loss for the third quarter of fiscal 2024 increased compared to the same period in the prior year, and its adjusted EBITDA deficit also increased due to lower research services gross profit. 23andMe ended December 31, 2023, with cash and cash equivalents of $242 million and adjusted its full year guidance following the third quarter results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.1%
Tags
earnings
-
Rhea-AI Summary
23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data into lists that were sold on the dark web. The company concealed these details when notifying affected customers. The lawsuit reveals that the hacker leaked a list of over 1 million Jewish customers expressly in retribution for the Israel-Hamas war, and a list of 350,000 Chinese customers upon request from a user with the alias 'Wuhan'. This disclosure threatens the safety of the customers. 23andMe has not informed the compromised customers that their personal genetic information was disclosed on the dark web, nor that they were specifically targeted. The PR also mentions the hacker's actions, prices for customer profiles, and 23andMe's attempt to shift the blame to customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.72%
Tags
none
-
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) has received FDA clearance for 23ME-01473 (‘1473), a natural killer (NK) cell activator intended to treat cancer. The drug targets ULBP6 to restore anti-tumor immunity through NK and T cells and is set to commence a Phase 1 clinical study in patients with solid tumors in the first half of 2024. '1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6 and inducing Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function. This drug has the potential to address a major unmet need in cancer treatment by targeting patients who may have or may develop tumor resistance to checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
clinical trial
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) has announced a month-long initiative to support Ava DuVernay's new film ORIGIN and its groundbreaking Seat16 program. The program allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to afford it. 23andMe will donate 100 seats daily for 23 days to support the program, ensuring that 10,000 young people across the nation get to experience ORIGIN. The film, inspired by Pulitzer Prize-winning journalist Isabel Wilkerson's novel 'Caste: The Origin of Our Discontents,' explores the mystery of history, the wonders of romance, and a fight for our future, while investigating the global phenomenon of caste and its dark influence on society. With an expansive cast that includes Academy Award nominee Aunjanue Ellis-Taylor, Jon Bernthal, and Niecy Nash-Betts, the film aims to educate a new generation through its storytelling.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) will report financial results for the FY2024 third quarter on February 7, 2024. The company aims to discuss its financial results and business progress through a webcast and Q&A platform for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
conferences earnings
-
Rhea-AI Summary
23andMe (NASDAQ: ME) experienced a significant data breach, affecting over 4 million users. The breach compromised personal information, including names, birth years, email addresses, genetic ancestry, potential relatives, and geolocation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary
23andMe (ME) suffered a massive data leak, compromising personal information of over 4 million users. The attack targeted data such as full name, birth year, email address, genetic ancestry, potential relatives, and geolocation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none
-
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) announces the expansion of the ongoing 23ME-00610 Phase 1/2a study to include 30 additional patients with advanced neuroendocrine and ovarian cancer. The study aims to evaluate the investigational antibody targeting CD200R1 and identify the optimal dose in alignment with recently published regulatory guidance. The ongoing study has shown appropriate safety profile and met pharmacodynamic biomarker and pharmacokinetic objectives. The Phase 2a portion of the study is being conducted with the highest tested dose from the Phase 1, and a second potentially efficacious dose will be evaluated in these additional patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.54%
Tags
clinical trial
-
Rhea-AI Summary
23andMe (ME) Announces Launch of 23andMe+ Total Health™ Membership and $20M Data License with GSK, Reports Q2 FY24 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.98%
Tags
earnings
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) has launched 23andMe+ Total Health, a comprehensive prevention-based health membership that includes clinical grade exome sequencing, biannual blood testing, and access to genetics-based clinical care, aiming to help individuals understand and benefit from their genetic information for disease prevention and early detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
23andMe Holding Co

Nasdaq:ME

ME Rankings

ME Stock Data

256.91M
312.08M
3.94%
43.08%
6.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About ME

23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.